Education
About Us
Working with TipRanks
Follow Us
Siemens Healthineers AG Unsponsored ADR (SMMNY)
OTHER OTC:SMMNY
Earnings Data
Report Date
May 12, 2026TBA (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
0.31Last Year’s EPS
0.32Same Quarter Last Year
Based on 1 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call presented a mix of strong operational performance in Imaging and Precision Therapy (solid growth, margin expansion ex-headwinds, strong Americas performance, product and partnership momentum, and a Moody's investment-grade rating) offset by significant challenges in Diagnostics driven by China-specific structural changes (VBP and reimbursement reductions), tariff and FX headwinds, and near-term guidance caution for Q2. Management emphasized that core synergies and operational improvements largely offset macro headwinds in Q1 and confirmed the full-year outlook, but Diagnostics and China pose material, near-term headwinds that may temper segment-level performance.Company Guidance
Strong start to fiscal 2026 and outlook confirmed
Company reported a good start to FY2026 and confirmed its full-year revenue growth and adjusted EPS outlook, citing strong operational performance in core businesses that offsets material headwinds.
Imaging and Precision Therapy growth
Synergetic portfolio (Imaging and Precision Therapy) delivered strong underlying growth (~6% combined): Imaging revenue growth of 5.7% and Precision Therapy growth of 5.9%, with equipment book-to-bill of 1.12.
Operational margin expansion (ex headwinds)
Operational margin expansion excluding tariffs and FX: Imaging operational margin expansion north of 100 basis points; Precision Therapy delivered almost 400 basis points operational margin expansion; group operational margin expansion ~200 basis points when excluding tariffs/FX.
Imaging adjusted EBIT margin and segment profitability
Imaging adjusted EBIT margin reported at 21.6%, reflecting strong operational margin improvement despite prior-year special items and current tariffs/FX headwinds.
Varian performance within Precision Therapy
Varian contributed 9% revenue growth to Precision Therapy and helped lift Varian/segment margins (Varian represented ~60% of the segment and Varian-related special items contributed meaningfully to the quarter's margin improvement).
Adjusted EPS resilient after adjusting for headwinds
Reported adjusted EPS was down ~3% year-over-year (EUR 0.02), but excluding tariffs and foreign exchange headwinds (~EUR 0.10 in Q1) adjusted EPS grew ~17% operationally; operational EPS improvement in Q1 was ~EUR 0.08, supporting the FY26 EPS improvement target (~EUR 0.25).
Regional strength: Americas
Americas region grew 9%, contributing strongly to group revenue growth and reflecting continued demand in key markets.
Atellica franchise momentum
Atellica franchise grew roughly 20% in Q1 and now represents almost 70% of core lab sales, indicating strong portfolio adoption in diagnostics outside China.
Strategic partnerships and commercial wins
New 10-year value partnership with Onvida (Southern Arizona) includes a $55 million capital equipment commitment and is expected to exceed $100 million in total value; Vietnam delivered 45 systems across 18 hospitals/clinics in December, including 2 Photon Counting CT systems.
Innovation and product differentiation
Showcased AI-enabled and next-generation technology (Syngo.CT Coronary Cockpit, Photon Counting CT, interventional MRI, new angiography systems with real-time AI denoising), reflecting continued R&D and clinical differentiation.
Credit/finance milestone
Received a strong investment-grade rating from Moody's, a key milestone supporting preparations for deconsolidation and refinancing and demonstrating financial resilience.
Siemens Healthineers AG Unsponsored ADR (SMMNY) Earnings, Revenues Date & History
SMMNY Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
SMMNY Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Jan 29, 2026 | $25.00 | $24.72 | -1.11% |
Nov 05, 2025 | $27.89 | $25.45 | -8.73% |
Jul 30, 2025 | $27.55 | $28.00 | +1.60% |
May 07, 2025 | $26.49 | $26.09 | -1.50% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Siemens Healthineers AG Unsponsored ADR (SMMNY) report earnings?
Siemens Healthineers AG Unsponsored ADR (SMMNY) is schdueled to report earning on May 12, 2026, TBA (Confirmed).
What is Siemens Healthineers AG Unsponsored ADR (SMMNY) earnings time?
Siemens Healthineers AG Unsponsored ADR (SMMNY) earnings time is at May 12, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is SMMNY EPS forecast?
SMMNY EPS forecast for the fiscal quarter 2026 (Q2) is 0.31.